Who are Etavopivat A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BG00012 (DMF) (Tecfidera®.), Etavopivat Tablets High dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etavopivat-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Etavopivat A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Etavopivat A (Etavopivat A) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nrf2 activator. Area: Hematology/Oncology.

phase 3 Nrf2 activator Nrf2 (NFE2L2) Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Etavopivat A (Etavopivat A) — Novo Nordisk A/S. Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase fetal hemoglobin (HbF) production and reduce hemolysis in patients with sickle cell disease.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Etavopivat A TARGET	Etavopivat A	Novo Nordisk A/S	phase 3	Nrf2 activator	Nrf2 (NFE2L2)
BG00012 (DMF) (Tecfidera®.)	BG00012 (DMF) (Tecfidera®.)	Multiple Sclerosis Center of Northeastern New York	marketed	Fumaric acid ester; Nrf2 activator	Nuclear factor erythroid 2-related factor 2 (Nrf2)
Etavopivat Tablets High dose	Etavopivat Tablets High dose	Forma Therapeutics, Inc.	phase 3	Nrf2 activator	Nrf2 (NFE2L2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nrf2 activator class)

Forma Therapeutics, Inc. · 1 drug in this class
Novo Nordisk A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etavopivat A — Competitive Intelligence Brief. https://druglandscape.com/ci/etavopivat-a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing